Zentalis and X4 Pharmaceuticals Announce Executive Inducement Grants

Zentalis Pharmaceuticals and X4 Pharmaceuticals have both disclosed new equity incentive grants awarded to executives under Nasdaq listing rule 5635(c)(4). The compensation packages are designed to attract and retain key leadership talent amid competitive industry hiring practices.